MedTrace Logo

Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer

NCT00210028 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2006-11-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the objective response rate when ZARNESTRA is added to treatment with tamoxifen

Conditions

  • Breast Neoplasms

Interventions

DRUG

Tamoxifen

DRUG

Zarnestra

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    collaborator INDUSTRY

  • Institut Claudius Regaud

    lead OTHER

Principal Investigators

  • Henri Roché, Pr · Institut Claudius Regaud

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2008-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210028 on ClinicalTrials.gov